Molecular heterogeneity in glioblastoma: Therapeutic opportunities and challenges

Seminars in Oncology

Volumn 38, Issue 2, 2011, Pages 243-253

  Nicholas, M Kelly ^a,b   Lukas, Rimas V ^a   Chmura, Steven ^a   Yamini, Bakhtihar ^a   Lesniak, MacIej ^a   Pytel, Peter ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO N [4 CHLORO 3 (2 PYRIDINYL)PHENYL] 4 METHANESULFONYLBENZAMIDE; AFATINIB; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; CILENGITIDE; DASATINIB; ENZASTAURIN; EPOTHILONE B; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; MARIMASTAT; NELFINAVIR; PAZOPANIB; PF 299804; PRINOMASTAT; RAPAMYCIN; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; UNINDEXED DRUG; VANDETANIB; VATALANIB; VORINOSTAT; XL 184;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; DRUG DELIVERY SYSTEM; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLIOBLASTOMA; HISTOGENESIS; HUMAN; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; NEURAL STEM CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79952947661     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.01.009     Document Type: Article

References (98)

1. D. Schiffer, L. Annovazzi, V. Caldera, and M. Mellai On the origin and growth of gliomas Anticancer Res 30 2010 1977 1998
2. J. Li, M. Wang, M. Won, E.G. Shaw, C. Coughlin, W.J. Curran Jr, and M.P. Mehta Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma Int J Radiat Oncol Biol Phys 2010 Sep 30 [Epub ahead of print]
3. B. Purow, and D. Schiff Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol 5 2009 419 426
4. H. Colman, and K. Aldape Molecular predictors in glioblastoma: toward personalized therapy Arch Neurol 65 2008 877 883 (Pubitemid 352008470)
5. M. Labussiere, X.W. Wang, A. Idbaih, F. Ducray, and M. Sanson Prognostic markers in gliomas Future Oncol 6 2010 733 739
6. J.H. Globus, and I. Strauss Spongioblastoma multiforme Arch Neurol Psychiatr 1925 139 151
7. H. Stroebe Uber Enstehung und Bau der Hirnglioma Beitr Pathol Anat 18 1895 405 485
8. J. Strauss, and J.H. Globus Spongioblastoma with unusually rapid growth following decompression Neurol Bull NY 1 1918 273 279
9. H. Ribbert Uber das spongioblastom und das gliom Virchows Arch 223 1918 195 213
10. P. Bailey, and H. Cushing A classification of the tumors of the glioma group on a histogenetic basis with a correlation study of prognosis 1925 Lippincott Philadelphia
11. K.J. Zulch Histological typing of tumors of the cental nervous system 1979 World Health Organization Geneva
12. D.N. Louis, H. Ohgaki, O.D. Wiestler, and W.K. Cavanee WHO classification of tumors of the central nervous system 2007 International Agency for Research on Cancer Lyon
13. H. Ohgaki, and P. Kliehues Genetic pathways to primary and secondary glioblastoma Am J Pathol 170 2007 1445 1453 (Pubitemid 47339290)
14. K.W. Kinzler, S.H. Bigner, and D.D. Bigner Identification of an amplified, highly expressed gene in a human glioma Science 236 1987 70 73 (Pubitemid 17056814)
15. D.W. Parsons, S. Jones, and X. Zhang An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
16. H. Yan, D.W. Parsons, and G. Jin ID1 and IDH2 mutations in gliomas N Engl J Med 360 2009 765 773
17. S.K. Rao, J. Edwards, A.D. Joshi, I.M. Siu, and G.J. Riggins A survey of glioblastoma genomic amplifications and deletions J Neurooncol 96 2010 169 179
18. S.H. Bigner, J. Mark, D.E. Bullard, M.S. Mahaley Jr, and D.D. Bigner Chromosomal evaluation in human malignant gliomas starts with specific and usually numerical deviations Cancer Genet Cytogenet 22 1986 121 135 (Pubitemid 16040864)
19. P.J. Mulholland, H. Fiegler, and C. Mazzanti Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme Cell Cycle 5 2006 783 791
20. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003 (Pubitemid 40349502)
21. M. Weller, J. Felsberg, and C. Hartmann Molecular predictors of progression-free and overall survival in patients with newly diagnosed globlastoma: a prospective translational study of the German Glioma Network J Clin Oncol 27 2009 5743 5750
22. M.A. Vogelbaum, B. Berkey, and D. Peereboom Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131 Neurooncol 11 2009 167 175
23. D. Hambardzumyan, N.M. Amankulor, K.Y. Helmy, O.J. Becher, and E.C. Holland Modeling adult gliomas using rcas/t-va technology Transl Oncol 2 2009 89 95
24. K.M. Reilly, and T. Jacks Genetically engineered mouse models of astrocytoma: GEMS in the rough? Semin Cancer Biol 11 2001 177 191
25. R. Simon Roadmap for developing and validating therapeutically relevant genomic classifiers J Clin Oncol 23 2005 7332 7341 (Pubitemid 46202346)
26. J.N. Rich, C. Hans, and B. Jones Gene expression profiling and genetic markers in glioblastoma survival Cancer Res 65 2005 4051 4058 (Pubitemid 40775641)
27. Y. Liang, N. Dieh, and N. Watson Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma Proc Natl Acad Sci U S A 102 2005 5813 5819
28. E. Cerami, E. Demir, N. Schultz, B.S. Taylor, and C. Sander Automated network analysis identifies core pathways in glioblastoma PLoS One 5 2010 e8918
29. H. Colman, L. Zhang, and E.P. Sulman A multigene predictor of outcome in glioblastoma Neurooncol 12 2010 49 57
30. The Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068
31. K.R. Yen, M.A. Bittinger, S.M. Su, and V.R. Fantin Cancer-associated IDH mutations: biomarker and therapeutic opportunities Oncogene 29 2010 L6409 L6417
32. R.P. Nagarajan, and J.F. Costello Epigenetic mechanisms in glioblastoma multiforme Semin Cancer Biol 19 2009 188 197
33. H. Noushmer, D.J. Weisenberger, and K. Diefes Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 2010 510 522
34. J. Laffaire, S. Everhard, and A. Idbaih Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis Neuro Oncol 2010 Epub ahead of print
35. E.>L. Jackson, and A. Alvarez-Buylla Characterization of adult neural stem cells and their relationship to brain tumors Cells Tissues Organs 188 2008 212 224 (Pubitemid 351962244)
36. E.L. Jackson, S. Garcia-Verdugo, and M. Gil-Perotin PDFRa-positive B cells are neural stem cells in the adult SVZ that form glioma-like growth in response to increased PDGF signaling Neuron 51 2006 187 199 (Pubitemid 44063617)
37. R. Galli, E. Binda, and U. Orfanelli Isolation and characterization of tumorigenic stem-like neural precursors from human glioblastoma Cancer Res 64 2004 7011 7021 (Pubitemid 39331011)
38. X. Yuan, J. Curtin, and Y. Xiong Isolation of cancer stem cells from adult glioblastoma multiforme Oncogene 23 2004 9392 9400 (Pubitemid 40069671)
39. H.S. Phillips, S. Kharbanda, and R. Chen Molecular subclasses of high grade gliom. predict prognosis, delineate a pattern of disease progression, and resemble stages in neurgoenesis Cancer Cell 9 2006 157 173 (Pubitemid 43357943)
40. S.Q. Bao, R.E. Wu, and Y. McLendon Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760
41. S. Bao, Q. Wu, and S. Sathornsumetee Stem cell-like glioma cells promote angioenesis through vascular endothelial growth factor Cancer Res 66 2006 7843 7848 (Pubitemid 44299144)
42. A. Inoue, H. Takahashi, and H. Harada Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity Int J Oncol 37 2010 1121 1131
43. A. Eramo, L. Ricci-Vitiani, and A. Zeuner Chemotherapy resistance of glioblastoma stem cells Cell Death Differ 13 2006 1238 1241 (Pubitemid 43905604)
44. A. Murat, E. Migliavacca, and T. Gorlia Stem cell-related "self renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemotherapy in glioblastoma J Clin Oncol 26 2008 3015 3024
45. K.S. Aboody, A. Brown, and N.G. Rainov Neural stem cells display extensive tropism for pathology in adult brain: evidence from intra-cranial gliomas Proc Natl Acad Sci U S A 97 2000 12846 12851
46. M. Dey, I.V. Ulasov, M.A. Tyler, A.M. Sonnabend, and M.S. Lesniak Cancer stem cells: the final frontier for glioma virotherapy Stem Cell Rev Rep 2010 Mar 18 [Epub ahead of print]
47. R.T. Frank, M. Edmiston, and S.E. Kendall Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies PLoS One 4 2009 e8314
48. J. Felsberg, M. Rapp, and S. Loeser Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients Clin Cancer Res 15 2009 6683 6693
49. S. Noda, A. El-Jawahri, D. Patel, T. Lautenschlaeger, M. Siedow, and A. Chakravarti Molecular advances of brain tumors in radiation oncology Semin Radiat Oncol 19 2009 171 178
50. M. Ueno Mechanisms of the penetration of blood-borne substances into the brain Curr Neuropharmacol 7 2009 142 149
51. Z. Gou, J. Zhu, L. Zhao, Q. Luo, and X. Jin Expression and clinical significance of multidrug resistance proteins in brain tumors J Exp Clin Cancer Res 29 2010 122 128
52. C. Buonerba, G. Di Lorenzo, and A. Marinelli A comprehensive outlook on intracerebral therapy of malignant gliomas Crit Rev Oncol Hematol 2010 Sep 29 [Epub ahead of print]
53. D.S. Bidros, J.K. Liu, and M.A. Vogelbaum Future of convection-enhanced delivery in the treatment of brain tumors Future Oncol 6 2010 117 125
54. S. Ferguson, and M.S. Lesniak Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors Curr Drug Deliv 4 2007 169 180 (Pubitemid 46557493)
55. N.D. Doolittle, L.E. Abrey, and W.A. Bleyer New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting Clin Cancer Res 11 2005 421 428 (Pubitemid 40116864)
56. K.A. Cassady, and J.N. Parker Herpesvirus vectors for therapy of brain tumors Open Virol J 4 2010 103 108
57. C. Manzano-Gomez, and J. Fueyo Oncolytic adenoviruses for the treatment of brain tumors Curr Opin Mol Ther 12 2010 530 537
58. M.E. Stevens, and E.S. Newlands From triazines and triazenes to temozolomide Eur J Cancer 29A 1993 1045 1057
59. W.K. Yung, M.D. Prados, and R. Yaya-Tur Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse Temodal Brain Tumor Group J Clin Oncol 17 1995 2762 2771 (Pubitemid 29415233)
60. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma N Engl J Med 352 2005 987 996 (Pubitemid 40349501)
61. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
62. M.S. Ahluwalia, and C.L. Gladson Progress on antiangiogenic therapy for patients with malignant glioma J Oncol 2010 689018. [Epub ahead of print]
63. H.S. Friedman, M.D. Prados, and P.Y. Wen Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
64. T.T. Batchelor, D.G. Duda, and E. di Tomaso Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma J Clin Oncol 28 2010 2817 2823
65. E.G. Van Meir, C.G. Hadjipanayis, and A.D. Norden Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma CA Cancer J Clin 60 2010 166 193
66. R.V. Lukas, A. Boire, and M.K. Nicholas Emerging therapies for malignant glioma Expert Rev Anticancer Ther 7 2007 s29 s36
67. G. Minniti, R. Muni, G. Lanzetta, P. Marchetti, and R.M. Enrici Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents Anticancer Res 29 2009 5171 5184
68. P.C. De Witt Hamer Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies Neurooncol 12 2010 304 316
69. W.K. Yung, J.J. Vredenburgh, and T.F. Cloughesy Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study Neurooncology 10 2010 1051 1070
70. J.N. Rich, D.A. Reardon, and T. Perry Phase II trial of gefitinib in recurrent glioblastoma J Clin Oncol 22 2004 133 142 (Pubitemid 41095125)
71. E. Raymond, A.A. Brandes, and C. Dittrich Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study J Clin Oncol 26 2008 3659 3665
72. D.A. Reardon, A. DesJardins, and J.J. Vredenburgh A phase II trial of sorafenib (Nexavr) and protracted temozolomide for patients with recurrent glioblastoma Neuro-Oncology 10 2008 abstract MA-82
73. C. Chaskis, J. Sadones, A. Michotte, M. Duiardin, H. Breraert, and B. Nevrns A phase II trial of sunitinib in patients with recurrent high grade glioma J Clin Oncol 26 suppl 2008 abstract 13001
74. C. Belda-Iniesta, E. Carpeno jdc, E.C. Saenz, M. Gutierrez, R. Perona, and M.G. Baron Long term responses with cetuximab therapy in glioblastoma multiforme Cancer Biol Ther 5 2006 912 914
75. F.M. Iwamoto, R. Lamb, and H.I. Robins Phase II trial of pazopanib (GW736034) an oral lmulti-targeted angiogenesis inhibitor for adlts with recurrent glioblastoma (orth American Brain Tumor Consortium Study 09-02) Neurooncology 12 2010 655 661
76. D.A. Reardon, M.D. Groves, and P. Wen A phase II trial of lapatinib and pazopanib for patients with recurrent glioblastoma multiforme (GBM) Neurooncology 9 2007 abstract MA9-07
77. T.N. Kreisl, J.A. Butman, P.S. Albert, L. Kim, K. Moore, and H.A. Fine A phase II trial of vandetanib for patients with recurrent glioblastoma multiforme Neurooncology 10 2008 abstract MA-40
78. C. Conrad, H. Friedman, and D.A. Reardon A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM) J Clin Oncol 22 2004 (suppl; abstr1512)
79. D.A. Reardon, K.L. Fink, T. Mikkelsen, T.F. Cloughesy, A. O'Neill, and S. Plotkin Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J Clin Oncol 26 2008 5610 5617
80. E. Galanis, K.A. Jaeckle, M.J. Maurer, J.M. Reid, M.M. Ames, and J.S. Hardwick Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study J Clin Oncol 27 2009 2052 2058
81. T.F. Cloughesy, P.Y. Wen, H.I. Robins, S.M. Chang, M.D. Groves, and K.L. Fink Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study J Clin Oncol 24 2006 3651 3656 (Pubitemid 46630540)
82. J.G. Kuhn, S.M. Chang, and P.Y. Wen Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma J Clin Cancer Res 13 2007 7401 7406
83. E. Galanis, J.C. Buckner, M.J. Maurer, J.I. Kreisberg, K. Ballman, and J. Boni Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study J Clin Oncol 23 2005 5294 5304 (Pubitemid 46206983)
84. T.N. Kreisl, A.B. Lassman, P.S. Mischel, N. Rosen, H.I. Scher, and J. Teruya-Feldstein A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) J Neurooncol 92 2009 99 105
85. P. Tang, G. Roldan, and P.M. Brasher A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma J Neurooncol 78 2006 311 316 (Pubitemid 44018826)
86. M.D. Groves, V.K. Puduvalli, and K.R. Hess Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme J Clin Oncol 20 2002 1383 1388 (Pubitemid 34177446)
87. M.K. Nicholas, R.V. Lukas, N.F. Jafri, L. Faoro, and R. Salgia Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas Clin Cancer Res 12 2006 7261 7270 (Pubitemid 46095397)
88. I.K. Mellinghoff, M.Y. Wang, and I. Vivanco Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2005 2012 2024 (Pubitemid 41609094)
89. W.K. Yung, J.J. Vredenburgh, T.F. Cloughesy, P. Nghiemphu, B. Klencke, and M.R. Gilbert Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study Neurooncol 12 2010 1061 1070
90. J.J. Raizer, L.E. Abrey, and A.B. Lassman A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy Neurooncol l12 2010 95 103
91. N.A. de Vries, T. Buckle, J. Zhao, J.H. Beijnen, J.H. Schellens, and O. van Tellingen Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP Invest New Drugs 2010 Oct 21 [Epub ahead of print]
92. J.H. Sampson, G.E. Archer, D.A. Mitchell, A.B. Heimberger, and D.D. Bigner Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignan glioma Semin Immunol 20 2008 267 275
93. A.B. Heimberger, W. Sun, and S.F. Hussain Immunological responses in a patient with glioblastoma multiforme treated with sequential course of temozolomide and immunotherapy: case study Neurooncol 10 2008 98 103 (Pubitemid 351250906)
94. J.H. Sampson, A.B. Heimberger, and G.E. Archer Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma J Clin Oncol 28 2010 4722 4729
95. L.A. Johnson, and J.H. Sampson Immunotherapyp approaches for malignant glioma from 2007 to 2009 Curr Neurol Neurosci Rep 10 2010 259 266
96. R. Yamanaka Cell-and peptide-based immunotherapeutic approaches for glioma Trends Mol Med 14 2008 228 235
97. J.N. Sarkana, E. Galanis, K.A. Jaeckle, and J.C. Buckner Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma mltiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks Clin Cancer Res 16 2010 5573 5580
98. K. Pankh, and M.P. Peppelenbosch Kinome profiling of clinical cancer specimens Cancer Res 70 2010 2575 2578